RQ-PCR在慢性粒细胞白血病细胞BCR-ABL融合基因检测中的应用  

Application of real-time quantification polymerase chain reaction in detecting the expression of BCR-ABL in chronic myelogenous leukemia cells

作　　者：吴薇[1] 韩瑞玲[1] 张力[2] 李艳[1] 

机构地区：[1]武汉大学人民医院检验科,430060 [2]武汉大学人民医院血液内科,430060

出　　处：《检验医学与临床》2016年第22期3133-3134,3137,共3页Laboratory Medicine and Clinic

基　　金：国家自然科学基金资助项目(81200389;81501427);教育部高等学校博士学科点专项科研基金(20120141120077);湖北省自然科学基金资助项目(2016CFB456)

摘　　要：目的探讨采用实时荧光定量逆转录聚合酶链反应(RQ-PCR)技术检测慢性粒细胞白血病(CML)细胞的BCRABLp210融合基因的临床价值。方法应用RQ-PCR技术对60例CML患者骨髓细胞BCR-ABLp210融合基因进行定量检测分析。结果 60例BCR-ABLp210融合基因阳性的CML患者中,慢性期33例,加速期13例,急变期14例,且CML急变期患者BCR-ABLp210转录本水平明显高于慢性期和加速期患者。经异基因造血干细胞移植治疗或经伊马替尼治疗6个月后,BCRABLp210转录本水平均较6个月前明显降低。但这两种方法治疗CML患者12个月后的效果比较差异无统计学意义(P>0.05),而采用其他酪氨酸激酶抑制剂治疗CML 12个月后也可达到相似的治疗效果。结论 RQ-PCR技术监测CML患者细胞BCR-ABLp210融合基因表达有助于CML的诊断、治疗效果评价及微小残留的监测。Objective To explore the clinical significance of real-time quantitative polymerase chain reaction（RQ-PCR）in detecting BCR-ABLp210 fusion gene in chronic myelogenous leukemia（CML）cells.Methods The transcript level of BCR-ABLp210 was measured by RQ-PCR from the bone marrow cells of 60 CML patients.Results All of 60 CML patients were BCR-ABL positive.Among the 60 patients,33patients were in chronic phase,13 patients were in accelerated phase and 14 patients were in blast phase.In contrast,the transcript level of BCR-ABLp210 in blast phase was significantly higher than that in the other phases.Six months after the treatment with allogenic hematopoietic stem cell transplantation（allo-HSCT）or imatinib,the transcript level of BCR-ABLp210 was decreased.In addition,there was no significant difference between allo-HSCT and imatinib treatment after 12months（P〉0.05）.Meanwhile,the application of the other tyrosine kinase inhibitors had the similar results for CML after 12-month treatment.Conclusion The detection of BCR-ABLp210 transcript level by RQ-PCR contributes to the diagnosis,the evaluation of curative effect and the minimal residue detection.

关 键 词：慢性粒细胞白血病 BCR-ABL 实时荧光定量逆转录聚合酶链反应 

分 类 号：R733.72[医药卫生—肿瘤]